Regulation of apoptosis in prostate cancer

被引:91
作者
Gurumurthy, S
Vasudevan, KM
Rangnekar, VM
机构
[1] Univ Kentucky, Grad Ctr Toxicol, Lexington, KY USA
[2] Univ Kentucky, Dept Microbiol & Immunol, Lexington, KY USA
[3] Univ Kentucky, Dept Radiat Med, Lexington, KY USA
[4] Univ Kentucky, LP Markey Canc Ctr, Lexington, KY USA
关键词
prostate cancer; apoptosis; genes;
D O I
10.1023/A:1015583310759
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Transformation and malignant progression of prostate cancer is regulated by the inability of prostatic epithelial cells to undergo apoptosis rather than by increased cell proliferation. The basic apoptotic machinery of most prostate cancer cells is intact and the inability to undergo apoptosis is due to molecular alterations that result in failure to initiate or execute apoptotic pathways. This review discusses the role of anti-apoptotic proteins such as Bcl-2/Bcl(X)L, NF-kappaB, IGF, caveolin, and Akt, and pro-apoptotic molecules such as PTEN, p53, Bin1, TGF-beta, and Par-4 that can regulate progression of prostate cancer. In addition to highlighting the salient features of these molecules and their relevance in apoptosis, this review provides an appraisal of their therapeutic potential in prostate cancer. Molecular targeting of these proteins and/or their innate pro- or anti-apoptotic pathways, either singly or in combination, may be explored in conjunction with conventional and currently available experimental strategies for the treatment of both hormone-sensitive and hormone-resistant prostate cancer.
引用
收藏
页码:225 / 243
页数:19
相关论文
共 136 条
[11]  
Bruckheimer EM, 1999, SEMIN ONCOL, V26, P382
[12]   Apoptosis in prostate carcinogenesis - A growth regulator and a therapeutic target [J].
Bruckheimer, EM ;
Kyprianou, N .
CELL AND TISSUE RESEARCH, 2000, 301 (01) :153-162
[13]   Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP prostate cancer cells [J].
Burchardt, M ;
Burchardt, T ;
Shabsigh, A ;
Ghafar, M ;
Chen, MW ;
Anastasiadis, A ;
de la Taille, A ;
Kiss, A ;
Buttyan, R .
PROSTATE, 2001, 48 (04) :225-230
[14]  
Chakraborty M, 2001, CANCER RES, V61, P7255
[15]   Plasma insulin-like growth factor I and prostate cancer risk: A prospective study [J].
Chan, JM ;
Stampfer, MJ ;
Giovannucci, E ;
Gann, PH ;
Ma, J ;
Wilkinson, P ;
Hennekens, CH ;
Pollak, M .
SCIENCE, 1998, 279 (5350) :563-566
[16]   AKT/PKB and other D3 phosphoinositide-regulated kinases: Kinase activation by phosphoinositide-dependent phosphorylation [J].
Chan, TO ;
Rittenhouse, SE ;
Tsichlis, PN .
ANNUAL REVIEW OF BIOCHEMISTRY, 1999, 68 :965-1014
[17]  
DANIELPOUR D, 1994, CANCER RES, V54, P3413
[18]   Activation of NF-kappa B by antineoplastic agents - Role of protein kinase C [J].
Das, KC ;
White, CW .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (23) :14914-14920
[19]  
Davies MA, 1999, CANCER RES, V59, P2551
[20]  
Denmeade S R, 1996, Adv Pharmacol, V35, P281, DOI 10.1016/S1054-3589(08)60278-1